Orb1301489-5mg | XYLOBIOSE [6860-47-5] Clinisciences

XYLOBIOSE

SKU: orb1301489

Description

Xylobiose is a natural disaccharide with potential anti-obesity properties. Research indicates it may suppress fat accumulation and ameliorate associated metabolic disorders, making it a candidate for metabolic disease studies in both cellular and animal models.

Research Area

Cell Biology, Immunology & Inflammation, Metabolism Research, Signal Transduction

Images & Validation

−

Key Properties

−

CAS Number	6860-47-5
MW	282.24
Purity	98.00% (May vary between batches)
Formula	C₁₀H₁₈O₉
SMILES	O[C@@H]1CO[C@@H](O[C@@H]2COC(O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O
Target	TNF,IL Receptor,HSP,Tight Junction Protein
Solubility	DMSO:60 mg/mL (212.59 mM)

Bioactivity

−

In Vivo	Mice received a 60% high-fat diet supplemented with 15% d-xylose, 10% XYLOBIOSE, or 15% XYLOBIOSE as part of the total sucrose content of the diet for ten weeks. Body weight, fat and liver weights, fasting blood glucose, and blood lipids levels were significantly reduced with XYLOBIOSE supplementation. Levels of leptin and adipokine were also improved and lipogenic and adipogenic genes in mesenteric fat and liver were down-regulated with XYLOBIOSE supplementation. Furthermore, pro-inflammatory cytokines, fatty acid uptake, lipolysis, and β-oxidation-related gene expression levels in mesenteric fat were down-regulated with XYLOBIOSE supplementation.XYLOBIOSE exhibits anti-diabetic, hypolipogenic, and anti-inflammatory effects via regulation of the miR-122a/33a axis in db/db mice.
Animal Research	The mice were randomized into five groups: (a) a control group (Ctrl, n = 10) which received a diet of modified American Institute of Nutrition (AIN)-93G (17% of the calories are from fat); (b) a high fat diet (HFD)-induced obesity control group (HF, n = 13) which received a HFD comprised of 60% fat; (c) a xylose 15% group (Xylo 15) which received a HFD with 15% of the total sucrose replaced with d-xylose (n = 13); (d) an XYLOBIOSE 10% group (XYLOBIOSE 10, n = 13) which received a HFD with 10% of the total sucrose replaced by XYLOBIOSE; and (e) an XYLOBIOSE 15% group (XYLOBIOSE 15, n = 12) which received a HFD with 15% of the total sucrose replaced by XYLOBIOSE. Commercially available D-xylose was included as a positive control and was administered at a dose comparable to XYLOBIOSE. The mice were maintained on these diets according to their group for ten weeks prior to sacrifice. Body weight and food intake were measured twice a week.

In Vivo

Mice received a 60% high-fat diet supplemented with 15% d-xylose, 10% XYLOBIOSE, or 15% XYLOBIOSE as part of the total sucrose content of the diet for ten weeks. Body weight, fat and liver weights, fasting blood glucose, and blood lipids levels were significantly reduced with XYLOBIOSE supplementation. Levels of leptin and adipokine were also improved and lipogenic and adipogenic genes in mesenteric fat and liver were down-regulated with XYLOBIOSE supplementation. Furthermore, pro-inflammatory cytokines, fatty acid uptake, lipolysis, and β-oxidation-related gene expression levels in mesenteric fat were down-regulated with XYLOBIOSE supplementation.XYLOBIOSE exhibits anti-diabetic, hypolipogenic, and anti-inflammatory effects via regulation of the miR-122a/33a axis in db/db mice.

Animal Research

The mice were randomized into five groups: (a) a control group (Ctrl, n = 10) which received a diet of modified American Institute of Nutrition (AIN)-93G (17% of the calories are from fat); (b) a high fat diet (HFD)-induced obesity control group (HF, n = 13) which received a HFD comprised of 60% fat; (c) a xylose 15% group (Xylo 15) which received a HFD with 15% of the total sucrose replaced with d-xylose (n = 13); (d) an XYLOBIOSE 10% group (XYLOBIOSE 10, n = 13) which received a HFD with 10% of the total sucrose replaced by XYLOBIOSE; and (e) an XYLOBIOSE 15% group (XYLOBIOSE 15, n = 12) which received a HFD with 15% of the total sucrose replaced by XYLOBIOSE. Commercially available D-xylose was included as a positive control and was administered at a dose comparable to XYLOBIOSE. The mice were maintained on these diets according to their group for ten weeks prior to sacrifice. Body weight and food intake were measured twice a week.

Storage & Handling

−

Storage	-20°C
Expiration Date	12 months from date of receipt.
Disclaimer	For research use only

Alternative Names

−

Disaccharide, inhibit, Inhibitor, ILReceptor, IL-1β, IL Receptor, XYLOBIOSE, TNF-α

−

XYLOBIOSE [orb1220689]
Purity:
>98% (HPLC)
CAS Number:
6860-47-5
MW:
282.24
Formula:
C₁₀H₁₈O₉?
Sizes Available: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g

Compound Identifiers

PubChem CID

439538 ↗

Key Properties

−

No computed properties available.

Documents Download

Datasheet

Product Information

Download

Request a Document

Protocol Information

XYLOBIOSE (orb1301489)

Based on 0 reviews

Participating in our Biorbyt product reviews program enables you to support fellow scientists by sharing your firsthand experience with our products.

No reviews yet

XYLOBIOSE [6860-47-5]

Referencia orb1301489-5mg

Marca : Biorbyt

XYLOBIOSE

Description

Research Area

Images & Validation

Key Properties

Bioactivity

Storage & Handling

Alternative Names

XYLOBIOSE [orb1220689]

Compound Identifiers

Key Properties

Documents Download

Request a Document

Protocol Information

XYLOBIOSE (orb1301489)

Step 1: Enter information below

Step 2: Enter the in vivo formulation

Purity:	>98% (HPLC)
CAS Number:	6860-47-5
MW:	282.24
Formula:	C₁₀H₁₈O₉?